| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | KHS101 | CTRPv2 | pan-cancer | AAC | -0.013 | 0.7 |
| mRNA | 1S,3R-RSL-3 | CTRPv2 | pan-cancer | AAC | -0.011 | 0.7 |
| mRNA | sirolimus:bortezomib (250:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.012 | 0.7 |
| mRNA | hyperforin | CTRPv2 | pan-cancer | AAC | 0.013 | 0.7 |
| mRNA | BRD-K33514849 | CTRPv2 | pan-cancer | AAC | 0.14 | 0.7 |
| mRNA | BRD-K34222889 | CTRPv2 | pan-cancer | AAC | -0.01 | 0.7 |
| mRNA | HBX-41108 | CTRPv2 | pan-cancer | AAC | -0.014 | 0.7 |
| mRNA | SR1001 | CTRPv2 | pan-cancer | AAC | 0.012 | 0.8 |
| mRNA | tipifarnib | CTRPv2 | pan-cancer | AAC | -0.0098 | 0.8 |
| mRNA | Bax channel blocker | CTRPv2 | pan-cancer | AAC | 0.012 | 0.8 |